Medicalgorithmics: First Half of 2024 Brings New Contracts and Successful Strategy Execution; 132% Quarterly Growth in U.S. AI Services Revenue
In the first half of 2024, Medicalgorithmics – a technology company listed on the sWIG80 index – successfully continued acquiring new clients, focusing on monetizing signed contracts and increasing sales. Since announcing its 2023-2026 strategy last year, the company has secured 13 new partners, including five in the U.S., and expects to sign additional contracts soon. As a result of the strategy, developed in cooperation with BioFund – the company’s largest shareholder – there has been a significant increase in U.S. revenue from AI-based ECG signal analysis services, which now stands as the company’s primary product. In Q2 2024, revenues grew by 132% compared to Q1, with the number of patients examined in the U.S. rising by over 200%.
Medicalgorithmics has an agreement with American Heart of Poland for a study using VCAST
Medicalgorithmics, a technology company listed on the sWIG80 index, has signed an agreement with American Heart of Poland, operator of the Polish-American Heart Clinics network of cardiology departments, to collaborate on a research project conducted by Medicalgorithmics titled “Comparative Study of Predictive Models for Coronary Artery Stenosis Analysis.”